Vicarious Surgical Inc.

And welcome to Vicarious Surgical's third quarter 2022 earnings conference call. My name is Amber, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Caitlin Bosco with Vicarious. Caitlin, please proceed.

Thanks, Amber. Thank you all for participating in today's call. Earlier today, Vicarious Surgical released preliminary, unaudited financial results for the three months ended September 30th, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation those relating to our operating trends and future financial performance, expense management, market opportunity, and commercialization, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors set forth in our annual report on Form 10-K for the year ended December 31st, 2021, filed with the Securities and Exchange Commission on March 31st, 2022, and our other reports we may file with the SEC from time to time. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 7, 2022. Vicarious Surgical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. With that, I will turn the call over to Adam Sack, Chief Executive Officer.

Thanks, Kate. Good afternoon, everyone, and thank you for joining us on today's call. With me today is Bill Kelly, our Chief Financial Officer. I'd like to start by sharing my excitement for the progress we made in the third quarter. Since our last call, we completed the integration phase of our Beta 2 system build. As a reminder, Beta 2 represents a significant milestone for the company. Given the strong, positive Beta 1 feedback on the robot itself, the enhancements incorporated in Beta 2 predominantly focused on the ergonomics, surgeon input, and visualization aspects of the surgeon console. Nonetheless, improved imaging and enhanced sensing and motion capabilities were built into Beta 2 to further expand the surgeon's access and ability to move freely within the abdominal cavity and operate seamlessly. Time and again, we see the clinical relevance of these features in our cadaver labs and continue to be very encouraged by the feedback from our preclinical testing. We look forward to formally showcasing the Beta 2 system at our demonstration day in December. I'd like to thank our partners at UH and HCA for their invaluable input on the Beta 2 design. In July of this year, we formalized our work with these hospital systems through the execution of two Center of Excellence agreements. At the forefront of innovation, HCA Healthcare and UH are widely recognized leaders in supporting and developing cutting-edge technology that delivers improved patient outcomes and advances the field of healthcare. Our work with each system extends far beyond post-market surgeon training. Our agreements outline plans for extensive development, clinical, verification, validation, and launch phases of bringing our full product ecosystem to market. In addition to these existing partnerships, We are pleased to share that we recently executed a strategic hospital system collaboration agreement with Pittsburgh Creates, an innovation center that fosters collaboration between surgeons and healthcare professionals with the expansive resources of the University of Pittsburgh and the University of Pittsburgh Medical Center. UPMC and Pittsburgh Creates offer unique access to collaborate with not only clinicians and hospital administrators, but also with the payers of the UPMC insurance umbrella, helping to ensure that our initial product offering meets not just the needs of patients, surgeons, and hospitals, but payers as well. With this agreement, we also gain access to the Advanced Center for Preclinical Studies within the University of Pittsburgh. This institution is a full-service testing and training facility that supports exploratory and preclinical testing of medical devices, and offers on-site capabilities for surgeon training and qualification. The agreement further expands our access to surgeon and administrator expertise across testing, training, and regulatory processes and provides critical clinical insight and support as we advance the development and finalization of our system and progress toward regulatory submission. In that regard, We continue to closely and routinely engage with the FDA as we plan for our upcoming pre-market IDE clinical trial and are encouraged by our interactions with the agency to date. Following our initial filing, we intend to file for three additional indications, inguinal hernia, cholecystectomy, and hysterectomy. By maintaining a close cadence of regulatory submission, we plan to offer an extensive set of use cases relatively early on in our commercial launch. Overall, we remain focused on our number one priority, system finalization, as we look forward to sharing more of our clinical trial strategy over the coming quarters. In October, we announced the appointment of Beverly Huss to our board of directors. Bev is a respected industry veteran with an impressive background and decades of broad medical device experience, ranging across R&D, regulatory affairs, and commercials. We welcome Bev to the Vicarious Surgical team and look forward to leveraging her expertise and insights. Before I turn the call over to Bill, I'd like to say how proud I am of our team's successful execution while remaining uncompromising in our approach. We are intentional in our development with a focus on collaboration between our teams and the healthcare systems who will ultimately institute our final product into their practice. With that, I'll hand it over to Bill for a discussion of our third quarter financial results.